Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Docket Number (Optional)

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

## 101961-5126-US (7946,204-US) REJECTION OVER A "PRIOR" PATENT in re Application of: Shawn DeFrees Application No : 10/549,528 Filed: September 19, 2005 FOR INTRACELLULAR FORMATION OF PEPTIDE CONJUGATES percent interest in the instant application hereby disclaims, The owner\*. Novo Nordisk A/S 100 except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond as the term of said prior patent is defined in 35 U.S.C. 154 the expiration date of the full statutory term prior patent No. 7,157,277 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. in making the above discraimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; in releasent or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate, For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. thereby declare that all statements made herein of my own knowledge are true and that all statements made on in formation and belief are belie ved to be true; a nd further that these statements were made with the knowledge that willful false statements and the like so made are punis hable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may leopardize the validity of the application or any patent issued thereon. The undersigned is an attorney or agent of record. Reg. No. Signature Len S. Smith, Esq., Senior Counsel, Reg. No. 43,139 Typed or printed name (609) 987-5800 Telephone Number √ Terminal disclaimer fee under 37 CFR 1,20(d) included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. \*Statement\_under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner) Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete including gathering, proparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments Selection of the Conference of